BioStock: Curasight secures global licence agreement for uTRACE in prostate cancer
Back in 2021 Curasight presented promising phase II results from an investigator initiated phase II study with uTRACE in prostate cancer. About two years later, the company now secures a first licence deal for its theranostic platform. BioStock contacted CEO Ulrich Krasilnikoff to talk about what this means for the company and its development.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se